Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oberon: Esomeprazole for Peptic Ulcer Prevention in Low-Dose ASA Users
NCT00441727Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2007
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of esomeprazole in peptic ulcer disease (PUD), gastric ulcer and duodenal ulcer (3 arms), sponsored by AstraZeneca. Primary endpoint: Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s) at 26 weeks. Started Feb 2007; status: completed.
02
Drugs
esomeprazole
03
Conditions
peptic ulcer disease (PUD)gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on NCT00441727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00441727.